Search
forLearn
5 / 801 resultslearn fusidic acid
learn TDM-105795
learn Folligen Complex
learn Lactobacillus
Research
5 / 1000+ results
research Recessive Mutation in FAM83G Associated with Palmoplantar Keratoderma and Exuberant Scalp Hair
A mutation in the FAM83G gene is linked to skin and hair abnormalities in two related individuals.
research Pioneer factors govern super-enhancer dynamics in stem cell plasticity and lineage choice
Super-enhancers controlled by pioneer factors like SOX9 are crucial for stem cell adaptability and identity.
research Understanding skin morphogenesis across developmental, regenerative and evolutionary levels
The article concludes that studying how skin forms is key to understanding skin diseases and improving regenerative medicine.
research Wasabi leaf extract changes the expression levels of cytokine related genes in dermal papilla cells, which identified by the whole transcriptome
Wasabi leaf extract affects gene expression in skin cells.
research References
Community Join
5 / 1000+ resultscommunity mallia therapeutics 8T3 scd83 molecule for ffa/lpp mainly and aga
A user applied the 8T3 product for hair loss, targeting LPP and AGA, and plans to update on its effectiveness. The product uses a saline buffered phosphate vehicle, suitable for those intolerant to ethanolic vehicles.
community Selling KY19382 powder a novel activator of Wnt/β-catenin signaling Product
Selling KY19382 powder, a novel activator of Wnt/β-catenin signaling, and Kolliphor EL liquid for vehicle formulation. KY19382 is a growth agonist.
community Ethanol or PEG400 Carrier for RU58841 on Science bio
The conversation discusses the best carrier for RU58841, comparing Ethanol and PEG400. The user seeks advice on which carrier is more effective.
community I have heard that Amplifica - Scube3 initiate a human study for AGA, but I cannot find any information about it from clinictrial.gov. Amplifica did not state it is a phase 1 clinic trial or not, it says it is "The initiation of our first-in-human clinical study"
The conversation is about a user seeking information on a clinical trial by Amplifica - Scube3 for Androgenetic Alopecia (AGA). The user is unsure if it's a formal phase 1 study.
community JXL082 is not PP405 and Everychem followed the wrong lead
JXL082 is not the same as PP405, leading to a halt in sales and a plan to synthesize the real PP405. There is skepticism about the safety and effectiveness of JXL082 and PP405, with concerns about patent issues and the long-term impact on hair growth.